Key Points for Decision Makers {#FPar1}
==============================

The cost-effectiveness of fidaxomicin, vancomycin and metronidazole for treating *Clostridium difficile* infection (CDI) has been evaluated in a number of studies.The current systematic literature review summarises the results of these economic evaluations, highlighting that despite its higher acquisition cost, fidaxomicin is cost-effective versus metronidazole and vancomycin in these patients.These results have important implications for clinical practice given increasing restrictions on healthcare budgets.

Introduction {#Sec1}
============

The incidence of *Clostridium difficile* infection (CDI) has increased in the last decade as a result of large outbreaks, resistant strains, severe infection and the spread to new, previously unaffected patient groups without known risk factors \[[@CR1]\]. This is despite concerted efforts to improve prevention and curb spread in nosocomial settings \[[@CR2], [@CR3]\].

CDI has a substantial impact on patients. It is associated with significant morbidity, hospitalisation and mortality \[[@CR4], [@CR5]\], which are compounded by the highly recurrent nature of the infection. Approximately 25% of patients treated with vancomycin or metronidazole, two of the recommended treatment options for CDI in the USA and Europe, experience CDI recurrence \[[@CR6]--[@CR8]\]. In the USA, it has been estimated that CDI recurrence accounts for 75,000--175,000 additional cases per year \[[@CR3]\]. Furthermore, patients who have had a recurrence are at increased risk of further episodes \[[@CR9]\]; approximately 40--60% of patients with a first recurrence develop subsequent recurrences \[[@CR10]\]. This cycle of infection represents the greatest hurdle for recovery \[[@CR11]\] and exacerbates the significant morbidity and economic impact associated with CDI \[[@CR11], [@CR12]\].

Managing CDI is costly. In a previously published systematic review of 13 studies, the incremental costs of managing a primary CDI case ranged from US\$2871 to US\$4846 in the USA and US\$5243 to US\$8570 outside the USA \[[@CR13]\]. Costs include those for medication and laboratory tests \[[@CR13]\], but the biggest cost driver is extended hospitalisation. For example, in an EE conducted in the UK, estimated costs per case were £90 for medication, £87 for laboratory tests and £2691 for excess hospitalisation; the latter therefore represented 94% of the total cost \[[@CR14]\]. The costs associated with managing recurrent CDI appear to be even greater, reflecting not only re-hospitalisation, but also the need for environmental decontamination, rigorous hygiene in patient care, and in some cases, cohort isolation and ward closure \[[@CR15]\]. Indeed, in the systematic review \[[@CR13]\], cost estimates for recurrent cases varied from US\$13,655 to US\$18,067 in the USA and were estimated to be US\$13,655 outside the USA.

CDI recurrence following treatment with metronidazole or vancomycin is thought to be due to antibiotic-induced disruption of the gut flora and the inability of these agents to prevent the subsequent effects of infection with residual *C. difficile* spores \[[@CR9], [@CR16]\]. Fidaxomicin is a first-in-class macrocyclic antibiotic for CDI, which combines bactericidal activity against *C. difficile* \[[@CR17]\] with limited activity against components of the normal commensal gut flora (compared with vancomycin) \[[@CR18]\]. Unlike metronidazole and vancomycin, fidaxomicin also inhibits sporulation of *C. difficile* (ATCC 43255 and UK-14 strains) in vitro \[[@CR16]\] and it significantly reduced the spore count versus vancomycin in patients being treated for a first episode of CDI \[[@CR19]\]. Furthermore, fidaxomicin prevents subsequent recovery of spores, vegetative growth and toxin production even if residual spores remain following treatment \[[@CR20]\].

These characteristics of fidaxomicin appear to translate into tangible clinical benefits for patients. In two randomised, double-blind, phase III studies versus vancomycin in patients with CDI, fidaxomicin was associated with statistically significant improvements in recurrence rates and, hence, sustained cure rates \[[@CR21], [@CR22]\]. A recent meta-analysis of the data from these studies confirmed these statistically significant improvements, and similar results were obtained in subgroup analyses of patients with severe and non-severe CDI \[[@CR23]\]. Furthermore, current evidence shows that the superiority of fidaxomicin over vancomycin is maintained in groups known to be at high risk of recurrence (e.g. in patients with a previous recurrence, those on concomitant antibiotic therapy, those aged \>65 years, those with cancer, or those with chronic renal insufficiency) \[[@CR24]\]. There are no direct comparative studies of fidaxomicin versus metronidazole, but according to indirect treatment comparisons using vancomycin as the data bridge, fidaxomicin was associated with improved sustained cure rates versus metronidazole in the overall CDI patient population \[[@CR23]\], as well as in various patient subgroups: patients aged ≥65 years, those with an initial episode, those on antibiotics, or those with severe or non-severe CDI \[[@CR25]\].

The acquisition cost of a course of fidaxomicin is substantially higher than that for metronidazole or vancomycin in Europe and the USA \[[@CR26]--[@CR29]\], which may limit first-line use in some settings. However, given the clinical benefits of fidaxomicin compared with other antibiotics, it is pragmatic to look beyond acquisition costs using economic evaluations (EEs). This is especially important given the high healthcare resource costs associated with managing recurrent CDI \[[@CR15]\]. The aim of the current systematic literature review was therefore to summarise published EEs that have assessed the cost-effectiveness of first-line agents, fidaxomicin, vancomycin and/or metronidazole, for treatment of CDI.

Methods {#Sec2}
=======

The methodology used to conduct the systematic review complied with guidance from the Centre for Reviews and Dissemination \[[@CR30]\] and the Cochrane Collaboration \[[@CR31]\]; however, grey literature was not included in the searches.

Electronic Database Search {#Sec3}
--------------------------

The following electronic databases were searched via the OVID platform on 18 August 2016:

MEDLINE^®^ In-Process and Other Non-Indexed Citations; MEDLINE^®^; Embase; and the Cochrane Library, incorporating the Health Technology Assessment Database and the NHS Economic Evaluation Database. Search terms used to identify relevant EEs are provided in the electronic supplementary material (ESM), online resource 1, Supplementary Table 1.

To be eligible for inclusion in the analysis, EEs had to meet pre-specified inclusion and exclusion criteria (see the ESM, Supplementary Table 2). Any cost-utility, cost-effectiveness, cost-benefit or cost-minimisation analyses that evaluated first-line antibiotic treatments (fidaxomicin, vancomycin and/or metronidazole) for CDI were eligible for inclusion. There were no restrictions in terms of the age of patients or the setting in which they were treated, the antibiotic dose or treatment regimen, the countries of interest, the language of the publication, or the publication date. Publications identified using the electronic database search were independently reviewed for relevance by two of the authors (HB and SM) on the basis of title and abstract. Full publications of potentially relevant citations were then obtained and examined in detail against the eligibility criteria. Disputes regarding eligibility were resolved through discussion between HB and SM. Reasons for exclusion were documented for all excluded citations. Analyses comparing faecal microbiota transplant (FMT) with only one intervention of interest were excluded, as FMT is only listed by guidelines for multiple recurrences (i.e. it is not a first-line treatment) \[[@CR32]--[@CR34]\] and is conducted by only a minority of hospitals in Europe. However, analyses comparing FMT with two or more first-line treatments were included so that data from the comparison of interest (e.g. vancomycin versus metronidazole) could be used.

The reference lists of eligible publications were also reviewed to identify any further potentially relevant publications that were not identified during the electronic database searches.

Conference Proceedings {#Sec4}
----------------------

In order to comply with Cochrane Collaboration guidelines \[[@CR31]\], relevant data from conference proceedings were also included. Thus, proceedings from the following conferences, which took place between 2013 and August 2016, were searched: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)---European and USA meetings; European Congress of Clinical Microbiology and Infectious Disease (ECCMID); Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); and IDWeek. A full list of the conferences included in the search is provided in Supplementary Table 3 (see the ESM).

The following search terms were used to identify relevant abstracts and posters within the conference proceedings: 'difficile', 'clostridium' and 'CDI'. Conference websites were searched to identify posters associated with published abstracts. If the poster was not available online, an attempt was made to contact the authors to obtain a copy.

As data presented at scientific conferences do not undergo the same rigorous peer review as those in full publications (and do not provide the same level of detail), a summary of the results excluding conference presentations was also conducted.

Data Extraction {#Sec5}
---------------

Key details from included EEs were extracted by HB and verified by SM; these included details of the following: the patient population \[diagnosis (e.g. initial episode, recurrent CDI), age, subgroups analysed\]; interventions for CDI; the model used; sources of clinical, cost and utility data; the results \[e.g. the incremental cost-effectiveness ratio, cost per outcome avoided, willingness-to-pay (WTP) threshold\]; and study conclusions. Any disputes were resolved through discussion. If the data were published as both abstract or poster and full publication, data were extracted from the latter. If more than one poster was available for a specific EE, the poster containing the most relevant data was used.

As well as cost-effectiveness results for the overall population with CDI, data for specific patient subgroups were also extracted, if reported. Subgroups of interest, which were guided by those reported in the pivotal phase III trials comparing fidaxomicin with vancomycin \[[@CR21], [@CR22]\], included patients with recurrent CDI, those at increased risk of mortality or recurrence, and those with severe CDI.

Quality Appraisal {#Sec6}
-----------------

The quality of the economic evidence reported in included full publications was assessed using the 36-item checklist of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal Specification for submission of evidence (January 2015), adapted from Drummond and Jefferson \[[@CR35]\]. This tool was used to assess the EE design, data collection methods, and analysis and interpretation of the results. The quality of conference abstracts and posters was not evaluated as they generally contain insufficient information to allow quality to be assessed rigorously.

Results {#Sec7}
=======

Identification of Included Economic Evaluations {#Sec8}
-----------------------------------------------

The number of citations retrieved and subsequently included in the analysis is summarised in Supplementary Fig. 1 (see the ESM). A total of 217 citations were retrieved from the electronic database search; 178 were subsequently excluded, and full publications were obtained for the remaining 39 citations. Based on review of the full publications, an additional 13 citations were excluded (Supplementary Table 4). Thus, 26 publications from the electronic database searches were included in the systematic literature review. Searches of conference proceedings and reference lists of the included publications identified a further nine citations that met the eligibility criteria. Thus, a total of 35 publications \[[@CR26]--[@CR28], [@CR36]--[@CR66]\], reporting data from 27 unique EEs, were included in the systematic literature review (Table [1](#Tab1){ref-type="table"}).Table 1Economic evaluations (EEs) included in the systematic literature reviewEEInterventions studiedType of analysis and resultsEE conclusionFidaxomicinVancomycinMetronidazoleFMTAlowayesh 2012 \[[@CR36]\]\
Abstract\
USA✓✓CEA\
Fidaxomicin did not dominateVancomycin is the preferred choice as it is less costly and only slightly less effective\
Fidaxomicin cure rates would have to be 97% for it to be preferredBartsch 2013 \[[@CR37]\]\
Full publication\
USA✓^a^✓^b^✓^c^CUA\
'No fidaxomicin' is the dominant strategy based on a cost-effectiveness threshold of US\$50,000/QALY\
Fidaxomicin was the optimal strategy if the cost of one course was \<US\$496 and NAP1/B1/027 probability \<48%\
Fidaxomicin based on strain typing, \>US\$43.7 million/QALYFidaxomicin is not a cost-effective treatment option in the current epidemiologic CDI conditions, unless its cost is reduced to ≤US\$150 for all CDI cases or US\$160--US\$400 for patients with a non-NAP1/B1/027 strainBott 2012 \[[@CR39]\]\
Abstract\
North America✓✓CEA\
Vancomycin dominated fidaxomicin\
Fidaxomicin becomes more cost-effective if \>25.7 days spent in hospital for relapse or if cure rate for vancomycin falls below 75.6%Fidaxomicin was not cost-effective compared with vancomycin\
Fidaxomicin may be cost-effective in older patients, those with comorbidities, recurrent CDI or a high risk of relapseBrodszky 2014 \[[@CR40]\]\
Poster\
Hungary✓✓CEA\
Cost per recurrence avoided with fidaxomicin: €5489\
Chance of fidaxomicin being cost-effective 95% if the WTP threshold ≥€7000Cost per recurrence avoided with fidaxomicin: €5489Gallagher 2015 \[[@CR42]\]\
Full publication\
USA✓✓CEA\
ICER not reportedReduced recurrence rate led to overall savings of US\$3047 per patient treated with fidaxomicinHeimann 2014 \[[@CR43]\]\
Poster\
Germany✓✓CEA\
ICER not reportedFidaxomicin is cost-effective for CDAD treatment in patients at high risk of recurrence, such as patients with cancerKarkow 2015 \[[@CR44]\]\
Poster\
USA✓✓CEA\
*FMT unavailable for recurrent episodes*\
Vancomycin dominant\
*FMT available for recurrent episodes*\
Vancomycin dominantVancomycin was cost-effective compared with metronidazole for the treatment of initial episodes of mild-to-moderate CDI regardless of FMT availabilityKonijeti 2014 \[[@CR46]\]; {Konijeti 2013 \[[@CR45]\]}\
Full publication; {abstract}\
USA✓✓✓✓CUA\
*Fidaxomicin vs. vancomycin*\
US\$184,023/QALY\
*Metronidazole vs. vancomycin*\
Vancomycin dominant\
*FMT via colonoscopy vs. vancomycin*\
US\$17,016\
*Fidaxomicin or metronidazole vs. FMT via colonoscopy*\
FMT via colonoscopy dominantFMT via colonoscopy was the most cost-effective strategy\
In settings where FMT was not available, vancomycin was the most cost-effective treatment when compared with fidaxomicin and metronidazoleLamotte 2013 \[[@CR47]\]\
Poster\
Belgium✓✓✓CUA\
Fidaxomicin dominated vancomycin and metronidazole in overall population, in those with severe CDI and in those with a first recurrence\
Based on cost-effectiveness threshold of €30,000/QALY, cost-effectiveness acceptable in 80% of all CDI casesFidaxomicin was dominant compared to vancomycin and metronidazole, generating additional QALYs with cost-savings in all CDI patients, and in subgroups of severe CDI and first recurrence CDI patientsLapointe-Shaw 2016 \[[@CR48]\]\
Full publication\
Canada✓^d^✓^d^✓^d^✓^e^CUA\
*FMT via colonoscopy vs. other treatments*\
FMT via colonoscopy dominant\
*Fidaxomicin vs. metronidazole*\
Fidaxomicin cost-effective (CAN\$25,968/QALY) based on WTP threshold of CAN\$50,000/QALY\
*Fidaxomicin vs. vancomycin*\
Fidaxomicin dominantFMT via colonoscopy was the most cost-effective strategy and dominated all other treatment strategies\
In settings where FMT was not available, fidaxomicin was cost-effective vs. metronidazole and vancomycinMadkour 2012 \[[@CR49]\]\
Abstract\
USA✓✓✓CEA\
Vancomycin dominant vs. metronidazole\
Vancomycin cost-effective probability if WTP threshold US\$0/additional cure, 40%\
Fidaxomicin more cost-effective if WTP threshold \>US\$22,000/additional cureVancomycin is the most cost-effective treatment for CDAD if WTP threshold ≤ US\$22,000/additional cure; fidaxomicin is cost-effective over this WTP thresholdMarković 2014 \[[@CR50]\]\
Full publication\
Serbia✓✓CEA\
 Fidaxomicin\
Cost/LYS = 2,977,621.51 RSD/LYS (SD 29,733.10) \[95% CI 2,947,888.41--3,000,354.62\]\
Cost-effective based on threshold of 53,307,040.00 RSD/LYS\
Cost per colectomy avoided = 10,175,146.97 RSD (SD 101,310.61) \[95% CI 10,073,536.36--10,276,757.50\]For the treatment of CDIC, fidaxomicin appeared cost-effective compared with vancomycin based on life-years saved, but not based on avoided colectomiesMassachi 2014 \[[@CR51]\]\
Poster\
USA✓✓✓✓CUA\
*Mild-to-moderate CDI*\
FMT dominant\
FMT favoured to fidaxomicin if:\
FMT cost \<US\$4515\
Cure rate: FMT \>0.883; fidaxomicin \<0.955\
Recurrence rate: FMT \<0.185; fidaxomicin \>0.02\
When FMT unavailable: fidaxomicin vs. metronidazole US\$4636/QALY; vancomycin dominated\
*Severe CDI*\
FMT dominant\
FMT favoured to vancomycin if:\
FMT cost \<US\$4860\
Cure rate: FMT \>0.79\
Recurrence rate: FMT \<0.36\
When FMT unavailable: vancomycin dominantFMT is the most cost-effective treatment option for mild-to-moderate, or severe CDI\
Fidaxomicin is the best alternative to FMT in mild-to-moderate CDI, and vancomycin is the best alternative to FMT in severe CDINathwani 2014 \[[@CR26]\]; {McCrea 2014 \[[@CR52]\]}\
Full publication; {poster}\
UK✓✓CUA\
At WTP thresholds of £20,000 and £30,000/QALY, fidaxomicin was cost-effective vs. vancomycin in severe CDI (£16,529/QALY) and dominated vancomycin for first recurrence\
The probability that fidaxomicin was cost-effective at a WTP threshold of £30,000/QALY was 60% for severe CDI and 68% in a first recurrenceFidaxomicin is cost-effective in patients with severe CDI and in patients with a first CDI recurrence vs. vancomycinPatel 2014 \[[@CR54]\]\
Abstract\
USA✓✓✓✓CUA\
*First recurrence*\
FMT most cost-effective, US\$1819/QALY (based on ICER threshold of US\$5000)\
Metronidazole second choice provided FMT cure rate \>82%\
*Second recurrence*\
FMT most cost-effective, provided FMT cure rate \>50%FMT was the most cost-effective treatment strategy for recurrent CDIPerras 2011 \[[@CR55]\]\
CADTH report\
Canada✓✓CEA\
 Vancomycin\
CAN\$1161/clinical cure\
*Pre-NAP1 epidemic*\
CAN\$946/clinical cure\
*NAP1 strain*\
CAN\$2,413/clinical cureVancomycin is cost-effective compared with metronidazole for the treatment of moderate to severe CDI, although the incremental cost is likely to increase as more virulent strains appearPetryszyn 2014 \[[@CR56]\]\
Abstract\
Poland✓✓CUA\
Fidaxomicin dominated vancomycinFidaxomicin resulted in more QALYs at lower costs for treating patients with severe CDI in Poland, so was considered cost-effectivePlanche 2014 \[[@CR57]\]; Nesnas 2014 \[[@CR53]\]\
Abstract^f^; abstract\
UK✓✓✓CEA\
Cost associated with fidaxomicin was £9469/case preventedAcquisition cost of fidaxomicin justified by savings from reduced recurrenceRubio-Terrés 2015 \[[@CR58]\]; {Cobo Reinoso 2014 \[[@CR41]\]}\
Full publication; {poster}\
Spain✓✓CUA\
Fidaxomicin dominated vancomycin in all subgroupsWhen fidaxomicin is compared to vancomycin in CDI patients with cancer, treated with concomitant antibiotic therapy or with renal impairment, the use of fidaxomicin would be expected to result in increased QALYs for patients and reduced overall costsSingh 2014 \[[@CR59]\]\
Abstract\
USA✓✓^g^✓✓^h^CEA\
Metronidazole cost-effective\
FMT via colonoscopy cost-effective\
All other interventions were dominatedOnly metronidazole and FMT via colonoscopy were cost-effective strategies for the treatment of primary CDI in patients in the ICUStranges 2013 \[[@CR28]\]\
Full publication\
USA✓✓CUA\
*Fidaxomicin*\
US\$67,576/QALY\
*Outpatient*\
US\$38,571/QALY\
*Inpatient*\
US\$75,111/QALY\
*Mild-to-moderate* CDI\
US\$32,020/QALY\
*Severe CDI*\
US\$352,994/QALY\
*NAP1/B1/027* strains\
Dominated\
*Concomitant AMT*\
US\$1487/QALY\
*Metronidazole in mild-to-moderate CDI*\
US\$40,513/QALY\
WTP threshold = US\$100,000/QALYFidaxomicin was cost-effective in most scenarios compared with vancomycin for treatment of CDI based on a WTP threshold of US\$100,000/QALY, and was shown to be robust in sensitivity analysesTrevor 2015 \[[@CR61]\]; {Trevor 2014 \[[@CR60]\]}\
Poster; poster\
France✓✓CUA\
WTP threshold = €50,000/QALY\
*All patients*\
Fidaxomicin cost-effective (€24,242/QALY)\
The cost per recurrence avoided = €1877\
Cost per faecal transplant avoided = €8967\
*Subgroups*\
Fidaxomicin cost-effective in all subgroups (severe CDI, first CDI recurrence, cancer, elderly, renal failure) except those using concomitant antibioticsFidaxomicin represents both a clinically effective and cost-effective treatment for patients with CDIvan Engen 2015 \[[@CR62]\]; {van Engen 2013 \[[@CR63]\]}\
Full publication; {poster}\
Ireland✓✓✓CUA\
*All patients*\
Fidaxomicin dominated vancomycin and/or metronidazole\
At a WTP threshold of €45,000/QALY, the probability of fidaxomicin being cost-effective was 82%\
*Subgroups*\
Fidaxomicin dominated in all subgroups (non-severe CDI, severe CDI and CDI recurrence)Fidaxomicin was dominant to the current standard-of-care therapy for CDIvan Engen 2014 \[[@CR64]\]\
Poster\
Sweden✓✓CUA\
Fidaxomicin was cost-effective vs. vancomycin in severe CDI: (€9,072/QALY) and dominated vancomycin in severe recurrent CDIFirst-line administration of fidaxomicin in severe CDI and severe recurrent CDI has the potential to improve patient outcomes as well as reduce the healthcare costs associated with CDI in SwedenVarier 2014 \[[@CR65]\]; {Biltaji 2014 \[[@CR38]\]}\
Full publication; {poster}\
USA✓✓✓CUA\
*FMT vs. metronidazole*\
US\$124,964/QALY\
*FMT vs. vancomycin*\
FMT dominant\
At a WTP threshold of US\$100,000/QALY, metronidazole was favoured in \~55% of model iterations and FMT in 38%FMT and vancomycin are more effective than metronidazole, but are also more costly\
FMT is only considered cost-effective with a high WTP thresholdWagner 2014 \[[@CR29]\]\
Full publication\
Canada✓✓CEA\
 Fidaxomicin\
CAN\$13,202/recurrence avoided\
 First recurrence of CDI at CEA entry\
CAN\$18,190/second recurrence avoided\
*Non-NAP1/B1/027 CDI strains*\
≥CAN\$10,504/recurrence avoided\
*NAP1/B1/027 CDI strains*\
≤CAN\$83,295/recurrence avoidedFidaxomicin is more costly for the Canadian healthcare system compared with vancomycin, and clinical benefits depend on the proportion of patients with the NAP1/B1/027 CDI strainWatt 2016 \[[@CR27]\]; {Watt 2015 \[[@CR66]\]}\
Full publication; {poster}\
Germany✓✓CUA\
WTP threshold = €50,000/QALY\
*≥1 recurrence*\
Fidaxomicin cost-effective\
*Severe CDI*\
Fidaxomicin cost-effective\
*Concomitant antibiotics*\
Fidaxomicin cost-effective\
*≥65 years*\
Fidaxomicin cost-effective\
*Renal impairment*\
Fidaxomicin cost-effective\
*Cancer*\
Fidaxomicin dominantIn patient subgroups with CDI at increased recurrence risk, fidaxomicin was cost-effective vs. vancomycin, and less costly and more effective in patients with cancerCitations in curly brackets are posters or abstracts that have subsequently been published in full*AMT* anti-microbial treatment, *CADTH* Canadian Agency for Drugs and Technologies in Health, *CDAD Clostridium difficile*-associated diarrhoea, *CDI Clostridium difficile* infection, *CDIC Clostridium difficile*-induced colitis, *CEA* cost-effectiveness analysis, *CUA* cost-utility analysis, *FMT* faecal microbiota transplant, *ICER* incremental cost-effectiveness ratio, *LYS* life-years saved, *QALY* quality-adjusted life-year, *RSD* Republic of Serbia dinars, *SD* standard deviation, *WTP* willingness to pay^a^Two treatment arms: fidaxomicin, or fidaxomicin based on strain typing results^b^Vancomycin given in 'no fidaxomicin' treatment arm if CDI severe or 'fidaxomicin based on strain typing' arm if positive for NAP1/B1/027 and CDI severe^c^Metronidazole given in 'no fidaxomicin' treatment arm if CDI non-severe or in 'fidaxomicin based on strain typing' arm if positive for NAP1/B1/027 and CDI non-severe^d^Followed by 6-week taper pulse course of vancomycin for subsequent recurrences^e^Three treatment arms: vancomycin plus FMT via enema; vancomycin plus FMT via nasogastric tube; vancomycin plus FMT via colonoscopy^f^Oral presentation, press release, and financial analysis also available from Astellas for Planche 2014 \[[@CR57]\]^g^Two treatment arms: high-dose vancomycin or low-dose vancomycin^h^Two treatment arms: FMT via colonoscopy or FMT via nasogastric tube

Of the 13 EEs reported as full publications, six \[[@CR26], [@CR27], [@CR46], [@CR58], [@CR62], [@CR65]\] had previously been presented at a conference \[[@CR38], [@CR41], [@CR45], [@CR52], [@CR63], [@CR66]\] and posters were sourced for all except one \[[@CR45]\]. For the remaining EEs, the data were reported in abstract (*n* = 7) \[[@CR36], [@CR39], [@CR49], [@CR53], [@CR54], [@CR56], [@CR57], [@CR59]\] or poster form (*n* = 7) only \[[@CR40], [@CR43], [@CR44], [@CR47], [@CR51], [@CR60], [@CR61], [@CR64]\].

In the remainder of this article, EEs are referenced using the full manuscript, if one is available, otherwise the abstract or poster is referenced. One UK EE has two associated abstracts \[[@CR53], [@CR57]\]; in this case, the Planche abstract \[[@CR57]\] is cited, as the key data were taken from this abstract. Also, one French EE has two associated posters \[[@CR60], [@CR61]\]; in this case, the 2014 poster is considered the key reference \[[@CR60]\]. A summary of duplicate publications is provided in Supplementary Fig. 2 (see the ESM).

Details of Included Economic Evaluations {#Sec9}
----------------------------------------

### Treatments Investigated {#Sec10}

Vancomycin was assessed in all 27 EEs, whereas fidaxomicin and metronidazole were investigated in 24 EEs \[[@CR26]--[@CR28], [@CR36], [@CR37], [@CR39], [@CR40], [@CR42], [@CR43], [@CR46]--[@CR51], [@CR54], [@CR56]--[@CR60], [@CR62], [@CR64]\] and 13 EEs \[[@CR37], [@CR44], [@CR46]--[@CR49], [@CR51], [@CR54], [@CR55], [@CR57], [@CR59], [@CR62], [@CR65]\], respectively. In two EEs \[[@CR37], [@CR57]\], vancomycin and metronidazole were combined in a single treatment arm and the intervention used was based on CDI severity or *C. difficile* strain. FMT was not a comparator of interest, but was a treatment arm in six of the EEs included \[[@CR46], [@CR48], [@CR51], [@CR54], [@CR59], [@CR65]\].

### Treatment Comparisons {#Sec11}

The most common treatment comparison was between fidaxomicin and vancomycin only, reported in 14 EEs \[[@CR26]--[@CR28], [@CR36], [@CR39], [@CR40], [@CR42], [@CR43], [@CR50], [@CR56], [@CR58], [@CR60], [@CR64]\]. Five EEs \[[@CR37], [@CR47], [@CR49], [@CR57], [@CR62]\] compared fidaxomicin with vancomycin and metronidazole. FMT was compared to the three antibiotics in five EEs \[[@CR46], [@CR48], [@CR51], [@CR54], [@CR59]\] and to vancomycin and metronidazole alone in one EE \[[@CR65]\]. Vancomycin and metronidazole only were compared in two EEs \[[@CR44], [@CR55]\].

### Model Types {#Sec12}

A Markov model was used in ten EEs \[[@CR26], [@CR27], [@CR47], [@CR48], [@CR50], [@CR56], [@CR58], [@CR60], [@CR62], [@CR64]\], and a decision-tree model was used in 11 EEs \[[@CR28], [@CR36], [@CR37], [@CR40], [@CR43], [@CR46], [@CR51], [@CR54], [@CR55], [@CR65]\]. Four EEs \[[@CR39], [@CR44], [@CR49], [@CR59]\] used a decision-analytic model, but no further details were provided in the publications. The two remaining EEs were not model-based, but used patient data from the authors' institutions \[[@CR42], [@CR57]\].

Five of the EEs comparing fidaxomicin and vancomycin \[[@CR26], [@CR47], [@CR58], [@CR62], [@CR64]\] were based on country adaptations of the same model (see the ESM, Supplementary Fig. 2).

### Economic Evaluation Perspectives {#Sec13}

Twelve countries were represented across the 27 EEs (see the ESM, Supplementary Fig. 3). These included the USA (11 EEs \[[@CR28], [@CR36], [@CR37], [@CR42], [@CR44], [@CR46], [@CR49], [@CR51], [@CR54], [@CR59], [@CR65]\]), Canada (three EEs \[[@CR48], [@CR55]\]), the UK (two EEs \[[@CR26], [@CR57]\]) and Germany (two EEs \[[@CR27], [@CR43]\]). Overall, 24 of the EEs were conducted from a payer perspective \[[@CR26]--[@CR28], [@CR36], [@CR37], [@CR39], [@CR40], [@CR42], [@CR44], [@CR47]--[@CR50], [@CR54]--[@CR60], [@CR62], [@CR64], [@CR65]\] and three \[[@CR43], [@CR46], [@CR51]\] were conducted from a societal perspective.

### Willingness-to-Pay Thresholds {#Sec14}

WTP thresholds for the base-case analysis were reported in nine EEs \[[@CR26]--[@CR28], [@CR37], [@CR46], [@CR48], [@CR50], [@CR54], [@CR60]\]. The WTP thresholds were US\$100,000/QALY \[[@CR28]\], US\$50,000/QALY \[[@CR37], [@CR46]\] and US\$5,000/QALY \[[@CR54]\] in analyses conducted from the USA perspective. In other EEs, WTP thresholds were CAN\$50,000/QALY (Canada) \[[@CR48]\], €50,000/QALY (France \[[@CR60]\] and Germany \[[@CR27]\]), and £20,000 and £30,000 (Scotland) \[[@CR26]\]. In the final EE, the WTP threshold was 53,307,040.00 Republic of Serbia dinars per life-year saved \[[@CR50]\].

### Sponsorship of Economic Evaluations {#Sec15}

Information regarding sponsorship was available for 19 analyses. Nine \[[@CR26], [@CR27], [@CR40], [@CR47], [@CR57], [@CR58], [@CR60], [@CR62], [@CR64]\] were sponsored by the marketing authorisation holder of fidaxomicin \[Merck (previously Optimer Pharmaceuticals then Cubist Pharmaceuticals) in the USA; Astellas in Europe and Japan\]. Of the remaining analyses, funding (or part-funding) by industry was confirmed for only two \[[@CR43]\].

Quality Appraisal Results {#Sec16}
-------------------------

Quality appraisal of all 13 full publications was conducted \[[@CR26]--[@CR28], [@CR37], [@CR42], [@CR46], [@CR48], [@CR50], [@CR55], [@CR58], [@CR62], [@CR65]\]. In general, EEs were of good quality and reported in sufficient detail (see the ESM, Supplementary Table 5). EE design and analysis of results were generally well described, but reporting of data collection methodology was inconsistent between EEs. In particular, details of sources for effectiveness estimates, quantities of resource use, and justifications for the choice of model were only reported in a minority of publications.

Results of Economic Evaluations {#Sec17}
-------------------------------

The results and conclusions of each of the 27 EEs are summarised in Table [1](#Tab1){ref-type="table"}.

### Overall CDI Population {#Sec18}

Figure [1](#Fig1){ref-type="fig"} shows the results of the 27 EEs included. Fidaxomicin was cost-effective versus vancomycin or metronidazole in 14 of the 24 EEs (58.3%) in which it was evaluated \[[@CR26]--[@CR28], [@CR40], [@CR42], [@CR43], [@CR47], [@CR50], [@CR56]--[@CR58], [@CR60], [@CR62], [@CR64]\]. Five of the 24 EEs included FMT; when data for this therapy were excluded, fidaxomicin was found to be cost-effective in one of the EEs \[[@CR48]\]. When this scenario was added to the other fidaxomicin EEs, 15 of 24 EEs (62.5%) found fidaxomicin to be cost-effective versus vancomycin or metronidazole \[[@CR26]--[@CR28], [@CR40], [@CR42], [@CR43], [@CR47], [@CR48], [@CR50], [@CR56]--[@CR58], [@CR60], [@CR62], [@CR64]\]. When the analysis was restricted to data published in full manuscripts only (i.e. when data from abstracts/posters were excluded), fidaxomicin was cost-effective versus vancomycin or metronidazole in seven of 11 (63.6%) EEs \[[@CR26]--[@CR28], [@CR42], [@CR50], [@CR58], [@CR62]\] and cost-effectiveness was unclear in one study \[[@CR29]\]. When FMT data were excluded, fidaxomicin was cost-effective in one additional study \[[@CR48]\], i.e. in eight of 11 (72.7%) EEs overall.Fig. 1Number and percentage of EEs reporting positive and negative cost-effectiveness results for each treatment for CDI. *CDI Clostridium difficile* infection, *EE* economic evaluation, *FDX* fidaxomicin, *FMT* faecal microbiota transplant, *MTZ* metronidazole, *VNC* vancomycin. ^a^Number of EEs is \>27, as two EEs reported \>1 treatment to be cost-effective \[[@CR65]\]. ^b^Note that cost-effectiveness thresholds vary according to EE and region. ^c^FMT was evaluated in six EEs only, but there were multiple comparisons with other treatments in some EEs (also note that FMT was not included as a search term in the systematic literature review). ^d^EE compared FDX with 'no FDX' strategy (VNC or MTZ) \[[@CR37]\]. One EE was not included in the figure as the cost-effectiveness conclusion was unclear from the publication \[[@CR29]\]

Vancomycin was cost-effective versus fidaxomicin or metronidazole in five of the 27 EEs (18.5%) \[[@CR36], [@CR39], [@CR44], [@CR49], [@CR55]\]. Six of the 27 EEs included FMT, and when data for this therapy were excluded, vancomycin was found to be cost-effective in one of the EEs \[[@CR46]\]. When this scenario was added to the other vancomycin EEs, six of 27 EEs (22.2%) found vancomycin to be cost-effective versus fidaxomicin or metronidazole \[[@CR36], [@CR39], [@CR44], [@CR46], [@CR49], [@CR55]\]. When the analysis was restricted to data published in full manuscripts only, vancomycin was cost-effective versus fidaxomicin or metronidazole in one of 13 (7.7%) EEs \[[@CR55]\]. When FMT data were excluded, vancomycin was cost-effective in one additional study \[[@CR46]\], i.e. in two of 13 (15.4%) EEs overall.

Metronidazole was cost-effective versus fidaxomicin, vancomycin or FMT in two of the 13 EEs (15.4%) \[[@CR59], [@CR65]\]. When data for FMT were excluded, metronidazole was found to be cost-effective in one further EE \[[@CR54]\]. When this scenario was added to the other metronidazole EEs, three of 13 EEs (23.1%) found metronidazole to be cost-effective versus fidaxomicin, vancomycin or FMT \[[@CR54], [@CR59], [@CR65]\]. When the analysis was restricted to data published in full manuscripts only, metronidazole was cost-effective in one of five (20.0%) EEs \[[@CR65]\].

The 'vancomycin *or* metronidazole' strategy (treatment dependent on CDI severity or *C. difficile* strain) was cost-effective versus fidaxomicin in the one EE in which it was evaluated \[[@CR37]\]. FMT was cost-effective versus at least two of the three antibiotics (fidaxomicin, vancomycin, metronidazole) in all six EEs in which it was evaluated \[[@CR46], [@CR48], [@CR51], [@CR54], [@CR59], [@CR65]\].

The cost-effectiveness of interventions according to specific treatment comparisons, as reported in the included EEs, is summarised in Fig. [2](#Fig2){ref-type="fig"}. In the 14 EEs that compared only fidaxomicin and vancomycin, fidaxomicin was cost-effective in 11 (78.6%) \[[@CR26]--[@CR28], [@CR40], [@CR42], [@CR43], [@CR50], [@CR56], [@CR58], [@CR60], [@CR64]\]. In the five EEs comparing fidaxomicin, vancomycin and metronidazole, fidaxomicin was cost-effective in three (60%) \[[@CR47], [@CR62]\].Fig. 2Number of EEs reporting positive cost-effectiveness results for each treatment for CDI, according to specific treatment comparisons. *Numbers below x*-*axis* refer to the number of EEs reporting each treatment comparison. *CDI Clostridium difficile* infection, *EE* economic evaluation, *FDX* fidaxomicin, *FMT* faecal microbiota transplant, *MTZ* metronidazole, *VNC* vancomycin. ^a^EE compared FDX with 'no FDX' strategy (VNC or MTZ) \[[@CR37]\]. ^b^Cost-effectiveness conclusion unclear from publication \[[@CR29]\]. ^c^Both FMT and MTZ were considered to be cost-effective \[[@CR59]\]. ^d^MTZ cost-effective vs. FMT, and FMT cost-effective vs. VNC \[[@CR65]\]

The reported key cost-effectiveness drivers were rate of recurrence \[[@CR26]--[@CR28], [@CR40], [@CR47], [@CR51], [@CR60], [@CR62], [@CR64]\], drug costs \[[@CR37], [@CR46], [@CR51], [@CR59], [@CR65]\], cure rate \[[@CR27], [@CR28], [@CR36], [@CR39], [@CR46], [@CR51], [@CR54], [@CR59], [@CR64], [@CR65]\], time horizon \[[@CR47]\] and length of hospitalisation and associated costs \[[@CR26], [@CR28], [@CR36], [@CR39], [@CR55], [@CR62], [@CR64]\]. Cure rates related to clinical cure in three of the EEs \[[@CR27], [@CR36], [@CR64]\]; in the remaining EEs, it was unclear whether cure rates related to clinical cure or sustained cure.

### Patient Subgroups {#Sec19}

Sixteen of the EEs \[[@CR26]--[@CR28], [@CR39], [@CR43], [@CR46]--[@CR48], [@CR51], [@CR54], [@CR56], [@CR58], [@CR60], [@CR62], [@CR64]\] included in the systematic literature review evaluated the cost-effectiveness of CDI interventions in the patient subgroups of interest (recurrent CDI; those at higher risk of mortality or CDI recurrence; severe CDI). In 12 of these \[[@CR26], [@CR27], [@CR39], [@CR43], [@CR46], [@CR48], [@CR51], [@CR54], [@CR56], [@CR58], [@CR62]\], the analysis focused on the subgroup(s) of interest, while in the remaining four \[[@CR28], [@CR47], [@CR60], [@CR62]\], the overall CDI population was used for the base case analysis, with additional analyses in the subgroups of interest. Fidaxomicin was cost-effective in most of the EEs reporting subgroup results (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Number and percentage of EEs reporting positive and negative cost-effectiveness results for each treatment in patient subgroups of interest. *CDI Clostridium difficile* infection, *FDX* fidaxomicin, *FMT* faecal microbiota transplant, *MTZ* metronidazole, *VNC* vancomycin

Discussion {#Sec20}
==========

This systematic literature review identified 27 unique analyses that evaluated the cost-effectiveness of antibiotics used to treat CDI. In most of the EEs included, fidaxomicin was cost-effective compared with vancomycin or metronidazole. Similar results were obtained when the analyses were conducted in subgroups of patients with recurrent or severe CDI, and in those at higher risk of recurrence or mortality. Although this review has some limitations (which are discussed below), the results of the EEs are consistent with the clinical profile of fidaxomicin and the current evidence describing the costs of managing CDI. Two phase III, randomised, double-blind trials \[[@CR21], [@CR22]\] show a significant improvement in recurrence rates and sustained cure rates in favour of fidaxomicin versus vancomycin. While there are no direct comparative trials versus metronidazole, the results of an indirect treatment comparison indicate that fidaxomicin reduced recurrence and increased sustained cure versus metronidazole \[[@CR23]\]. These clinical data are consistent with the pharmacological profile of fidaxomicin, which has minimal effects on the gut flora and has a greater preventative effect on *C. difficile* sporulation and subsequent cell growth from spores, compared with the other two antibiotics \[[@CR16], [@CR67]\]. Given the significant economic impact associated with prolonged hospitalisation in patients with CDI, particularly for recurrent episodes \[[@CR13]--[@CR15]\], the results of the current systematic literature review indicate that fidaxomicin provides clinical and economic benefits despite having a higher acquisition cost.

FMT was cost-effective versus antibiotic treatment in all six of the EEs that were included. However, this procedure is only listed by guidelines for multiple recurrences \[[@CR32], [@CR33]\] and is conducted by only a minority of hospitals in Europe. Consequently, it was not included as a comparator of interest in the current analysis, so not all studies evaluating the cost-effectiveness of FMT will have been identified. In addition, information relating to specific methodology for FMT and the cost of carrying out the procedure is not publicly available and will vary from centre to centre. For this reason, it is difficult to evaluate the cost-effectiveness of FMT.

Speculating on the reasons why some EEs showed a particular CDI treatment to be cost-effective while others did not is difficult in view of the heterogeneity of the model input parameters, as well as the lack of information on these for some of the analyses published in abstract form. However, it may reflect differences in model input parameters for rates of recurrence, drug costs, cure rate, time horizon and length and cost of hospitalisation, as these were identified as key cost-effectiveness drivers in the EEs included. The issue of variability in the results of EEs has been highlighted previously, and one of the most commonly cited factors for generating variability in results between locations is the unit costs associated with particular resources \[[@CR68]\].

Results of a recently published cost-of-illness study conducted in a German hospital indicate that the costs of recurrence may have been underestimated previously \[[@CR69]\]. In that particular study, the direct treatment costs of CDI recurrence were estimated at €73,898 per patient with one or more recurrence \[[@CR69]\]; this is four times greater than the incremental cost estimates for recurrent CDI reported in the US-based systematic review mentioned above \[[@CR13]\]. It has also been shown that recurrent CDI has a greater impact on patients' quality of life than the initial episode \[[@CR70]\]. Taken together, these data suggest that fidaxomicin may be more cost-effective than suggested by the results of our systematic literature review of EEs. However, translating these cost-effectiveness results into different payer systems can be challenging. First, the incidence (and therefore economic impact) of recurrence may be underestimated, reflecting, in part, differences in the definition of recurrence between hospitals \[[@CR71]\]. Also, in certain settings, patients may present at different centres for initial and recurrent episodes \[[@CR69]\]; as budgetary control is often held at the hospital rather than regional level, the payer for the initial episode will not benefit from the reduction in later costs associated with reduced recurrence. Even if a patient is treated at the same hospital, there may be no financial penalty for recurrence, and consequently, individual hospitals may be less likely to use treatments with higher acquisition costs, but lower recurrence rates.

European guidelines for the management of CDI make treatment recommendations based on the severity of the infection and whether the infection is recurrent \[[@CR32]\]. For non-severe cases, metronidazole is recommended over fidaxomicin and vancomycin, while for recurrent cases, equal weight is given to fidaxomicin and vancomycin over metronidazole \[[@CR32]\]. In the USA, guidelines recommend metronidazole for mild-to-moderate CDI and vancomycin for severe infection \[[@CR33]\]. Although the World Society of Emergency Surgery recognises the place of fidaxomicin in patients with mild-to-moderate CDI at high risk of recurrence, it currently recommends fidaxomicin and vancomycin with equal weight for those with multiple recurrences \[[@CR72]\]. These recommendations are based on clinical data only and do not take cost-effectiveness into account. The current systematic literature review is informative in this regard, particularly in view of increased pressures to reduce costs in the healthcare sector. In Australia, treatment recommendations for CDI do take cost-effectiveness into consideration and fidaxomicin is recommended for those with multiple recurrences if they have a high risk of subsequent recurrence \[[@CR72]\]. Conversely, the Australian guidelines recommend that fidaxomicin is reserved for third-line use in severe, first-episode CDI due to uncertainty about cost-effectiveness versus conventional treatment options \[[@CR72]\]. In the study by Watt et al., which is included in the current analysis, fidaxomicin was shown to be cost-effective versus vancomycin and metronidazole in those with an initial CDI episode and in those with severe CDI, albeit from the perspective of the NHS in England \[[@CR25]\].

The analysis does have some limitations. These include limitations associated with the models used in the EEs (e.g. extrapolation of the outcomes to the model timelines) as well as limitations associated with the overall analysis, such as its non-quantitative nature and the heterogeneity of the EEs included, which varied according to the type of model used, the interventions analysed, the time horizons employed, the outcome measures reported, and the country perspectives from which the EEs were conducted. Country preferences vary in terms of drug acquisition costs, hospitalisation costs and how cost-effectiveness is assessed (e.g. cost/QALY, cost/recurrence avoided, cost/clinical cure); WTP thresholds, which generally equate to one to three times a country's gross domestic product \[[@CR73]\], also vary, with wealthier countries having a higher threshold. Thus, in countries with lower cost-effectiveness thresholds, fidaxomicin may not be interpreted to be cost-effective despite its beneficial clinical effects on recurrence and sustained cure. It should also be noted that in the USA, WTP thresholds are not formally used to make treatment decisions. Another limitation of the current analysis is that five of the EEs comparing fidaxomicin and vancomycin \[[@CR26], [@CR47], [@CR58], [@CR62], [@CR64]\] were based on country adaptations of the same model and therefore had similar inputs and assumptions. Also, some of the EEs were published in abstract or poster form only \[[@CR36], [@CR39], [@CR40], [@CR43], [@CR44], [@CR47], [@CR49], [@CR51], [@CR53], [@CR54], [@CR56], [@CR57], [@CR59]--[@CR61], [@CR64]\] and therefore contain only limited information on the details of the economic models; however, excluding these publications could potentially have introduced bias to the results and would have contravened the methodological guidelines of the Cochrane Collaboration \[[@CR31]\]. Nevertheless, when the analysis was restricted to data published in full manuscripts only, similar results were obtained to those for the full analysis. Finally, the 'grey literature' (e.g. data in company repositories, regulatory agency digital archives, industry investor reports and press releases, and institutional websites) was not searched, and therefore some relevant assessments of cost-effectiveness in CDI may have been omitted (i.e. publication bias may have been introduced). On the other hand, a strength of the analysis is that selection bias was avoided by a priori documentation of criteria for EE selection. Also, despite its limitations, this systematic literature review is the first to summarise the currently available information on the cost-effectiveness of antibiotic treatment for CDI. As such, it provides a general overview that may be useful for aiding treatment decisions.

In conclusion, the results of this systematic literature review indicate that in most EEs, fidaxomicin was cost-effective versus metronidazole or vancomycin in patients with CDI. Fidaxomicin was also cost-effective in most of the EEs that evaluated specific, higher-risk patient subgroups. In order to build on these data, updated indirect treatment comparison network analyses of the clinical effectiveness of antibiotic treatments for CDI would be desirable to allow a more integrated EE. Nevertheless, results from the current analysis are highly relevant given the high budgetary impact of managing CDI and the increasing restrictions on healthcare budgets. However, in order for the cost offsets of fidaxomicin to be realised, the true extent and impact of recurrent CDI must be more fully understood. Also, there needs to be a shift in focus from cost containment at the individual hospital level to cost evaluation at a national level. If these barriers can be addressed, first-line use of fidaxomicin has the potential to facilitate more efficient use of funds in clinical practice.
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